- -Agreement with leading drug-delivery company outlines plans to develop fast-acting, orally dissolving film for delivery of pharmaceutical-grade psilocybin
- -Cybin CEO notes that systemic bioavailability of film is projected to be high
- -Cybin focused on developing fungi-derived psychedelic, medicinal products to treat mental illness, other health conditions
Cybin Corp. announced that it has entered into a feasibility agreement with IntelGenx Corp., a leading drug-delivery company focused on the development and manufacturing of pharmaceutical delivery films (http://ibn.fm/TZeVy). The agreement outlines plans for the two companies to develop a fast-acting, orally dissolving film for the delivery of pharmaceutical-grade psilocybin.
“We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film,” said Cybin’s Chief Medical Officer Dr. Jukka Karjalainen. “Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic bioavailability of orally-dissolving psilocybin film is expected to be quite high. In addition, the dose of psilocybin administered by an orally dissolving film is expected to be a fraction of what is required in oral capsules. Taken together, these features have the potential to increase both the safety and efficacy of psilocybin when administered in this manner.”
Subject to receipt of all necessary regulatory approvals, the agreement allows both companies to capitalize on their strengths while partnering with a recognized expert in the space. Cybin is a mushroom life-sciences company focused on offering psychedelic and nutraceutical-based products. IntelGenx is recognized for its superior film technologies, including VersaFilm(R) and VetaFilm(TM), as well as its transdermal development and manufacturing capabilities.
“Cybin’s intention with an orally dissolving psilocybin film is to bypass the digestive system, which will provide faster-acting relief for individuals with anxiety disorders who require more immediate symptom relief,” noted Cybin CEO Paul Glavine.
According to IntelGenx CEO Dr. Horst G. Zerbe, the partnership “exemplifies both the versatility and clinical advantages of our VersaFilm(R) technology platform. In addition to offering patients a convenient method of administration, our technology offers superior drug bioavailability, which decreases both the amount of active pharmaceutical ingredient required per dose, as well as time to onset of action, which are paramount when treating distressing conditions such as anxiety. We are looking forward to working with Cybin to realize these potential benefits for patients struggling with mental health disorders.”
Cybin operates in the functional-mushroom market with a goal to develop fungi-derived medicinal products to treat mental illness and other health conditions. The business model of this early-stage, life-sciences company includes two wholly owned core subsidiaries: Serenity Life Sciences, focusing on advancing research and development of psilocybin-based pharmaceutical products, and Natures Journey Inc., developing medicinal nonpsychedelic nutraceutical products.
For more information about this company, please visit www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
